Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes after Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 117, Issue 8, 2016, Pages 1256-1266

  Barria Perez, Alberto E ^a   Rao, Sunil V ^b   Jolly, Sanjit J ^c   Pancholy, Samir B ^d   Plourde, Guillaume ^a   Rimac, Goran ^a   Poirier, Yann ^a   Costerousse, Olivier ^a   Bertrand, Olivier F ^a  

^a LAVAL UNIVERSITY   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d Wright Center for Graduate Medical Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRULOG; ANTITHROMBIN; FIBRINOLYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; STENT THROMBOSIS; CHEMICALLY INDUCED; HEALTH; INCIDENCE; MYOCARDIAL ISCHEMIA; POSTOPERATIVE HEMORRHAGE; THROMBOSIS;

ANTITHROMBINS; FIBRINOLYTIC AGENTS; GLOBAL HEALTH; HEPARIN; HIRUDINS; HUMANS; INCIDENCE; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 84958559644     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.01.015     Document Type: Article

References (43)

1. G.W. Stone, R. Mehran, and P.G. Steg Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes JACC Cardiovasc Interv 8 2015 225 227
2. M.A. Cavender, and M.S. Sabatine Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials Lancet 384 2014 599 606
3. O.F. Bertrand, S.S. Jolly, S.V. Rao, T. Patel, L. Belle, I. Bernat, G. Parodi, O. Costerousse, and T. Mann Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention Am J Cardiol 110 2012 599 606
4. A. Shahzad, I. Kemp, C. Mars, K. Wilson, C. Roome, R. Cooper, M. Andron, C. Appleby, M. Fisher, A. Khand, B. Kunadian, J.D. Mills, J.L. Morris, W.L. Morrison, S. Munir, N.D. Palmer, R.A. Perry, D.R. Ramsdale, P. Velavan, R.H. Stables HEAT-PPCI trial investigators Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 384 2014 1849 1858
5. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Open Med 3 2009 e123 e130
6. D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe, and S.B. Thacker Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group JAMA 283 2000 2008 2012
7. R. Mehran, S.V. Rao, D.L. Bhatt, C.M. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S.D. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J.F. Sabik, D.E. Cutlip, M.W. Krucoff, E.M. Ohman, P.G. Steg, and H. White Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
8. R. Wolfram, L. Leborgne, E. Cheneau, E.E. Pinnow, D.A. Canos, D. Hellinga, L.F. Satler, A.D. Pichard, K.M. Kent, and R. Waksman Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention Am J Cardiol 92 2003 1080 1083
9. H.S. Gurm, V. Rajagopal, R. Fathi, D. Vivekanathan, J.S. Yadav, D.L. Bhatt, S.G. Ellis, A.M. Lincoff, and E.J. Topol Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center Am J Cardiol 95 2005 716 721
10. S.W. Rha, P.K. Kuchulakanti, R. Pakala, E. Cheneau, E. Pinnow, R. Torguson, A.D. Pichard, L.F. Satler, W.O. Suddath, K.M. Kent, J. Lindsay, and R. Waksman Bivalirudin versus heparin as an antithrombotic agent in patients who undergo percutaneous saphenous vein graft intervention with a distal protection device Am J Cardiol 96 2005 67 70
11. W.W. Chu, P.K. Kuchulakanti, B. Wang, R. Torguson, L.C. Clavijo, A.D. Pichard, W.O. Suddath, L.F. Satler, K.M. Kent, and R. Waksman Bivalirudin versus unfractionated heparin in patients undergoing percutaneous coronary intervention after acute myocardial infarction Cardiovasc Revasc Med 7 2006 132 135
12. H.S. Gurm, D.E. Smith, S.J. Chetcuti, D. Share, S. Khanal, A. Riba, A.J. Carter, T. Lalonde, E. Kline-Rogers, M. O'Donnell, W. O'Neill, R. Safian, M. Moscucci Blue Cross Blue Shield of Michigan Cardiovascular Consortium Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium J Interv Cardiol 20 2007 197 203
13. L. Bonello, A. de Labriolle, P. Roy, D.H. Steinberg, T.L. Pinto Slottow, Z. Xue, K. Kaneshige, R. Torguson, W.O. Suddath, L.F. Satler, K.M. Kent, A.D. Pichard, and R. Waksman Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty Cardiovasc Revasc Med 10 2009 156 161
14. G. Lemesle, L. Bonello, A. De Labriolle, D.H. Steinberg, P. Roy, T.L. Slottow, R. Torguson, K. Kaneshige, Z. Xue, W.O. Suddath, L.F. Satler, K.M. Kent, J. Lindsay, A.D. Pichard, and R. Waksman Impact of bivalirudin use on outcomes in nonagenarians undergoing percutaneous coronary intervention J Interv Cardiol 22 2009 61 67
15. G. Lemesle, A. De Labriolle, L. Bonello, A. Syed, S. Collins, G. Maluenda, R. Torguson, K. Kaneshige, Z. Xue, W.O. Suddath, L.F. Satler, K.M. Kent, J. Lindsay, A.D. Pichard, and R. Waksman Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention Catheter Cardiovasc Interv 74 2009 428 435
16. C. Delhaye, G. Maluenda, K. Wakabayashi, I. Ben-Dor, S.D. Collins, A.I. Syed, M.A. Gonzalez, M.A. Gaglia, R. Torguson, Z. Xue, W.O. Suddath, L.F. Satler, K.M. Kent, J. Lindsay, A.D. Pichard, and R. Waksman Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention Am J Cardiol 105 2010 297 301
17. J.B. Lindsey, D.J. Cohen, J.M. Stolker, S.K. Meht, E. Mahoney, K. Robertus, J.A. House, K. Kennedy, L. Riggs, S.V. Rao, and S.P. Marso The impact of bivalirudin on percutaneous coronary intervention-related bleeding EuroIntervention 6 2010 206 213
18. R.D. Lopes, E.D. Peterson, A.Y. Chen, M.T. Roe, T.Y. Wang, E.M. Ohman, D.J. Magid, P.M. Ho, S.D. Wiviott, B.M. Scirica, and K.P. Alexander Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry JACC Cardiovasc Interv 3 2010 669 677
19. S. Schulz, J. Mehilli, F.J. Neumann, T. Schuster, S. Massberg, C. Valina, M. Seyfarth, J. Pache, K.L. Laugwitz, H.J. Buttner, G. Ndrepepa, A. Schomig, A. Kastrati, S. Intracoronary Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3A Trial Investigators ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention Eur Heart J 31 2010 2482 2491
20. S. Bangalore, D.J. Cohen, N.S. Kleiman, T. Regev-Beinart, S.V. Rao, M.J. Pencina, L. Mauri EVENT Registry Investigators, Boston, MA Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry Circ Cardiovasc Interv 4 2011 463 473
21. J. MacHaalany, E. Abdelaal, Y. Bataille, G. Plourde, P. Duranleau-Gagnon, E. Larose, J.P. Dery, G. Barbeau, S. Rinfret, J. Rodes-Cabau, R. De Larochelliere, L. Roy, O. Costerousse, and O.F. Bertrand Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention Am J Cardiol 110 2012 1742 1748
22. B. Hibbert, A. MacDougall, M. Labinaz, E.R. O'Brien, D.Y. So, A. Dick, C. Glover, M. Froeschl, J.F. Marquis, G.A. Wells, M. Blondeau, and M.R. Le May Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry Circ Cardiovasc Interv 5 2012 805 812
23. S. Bangalore, M.J. Pencina, N.S. Kleiman, and D.J. Cohen Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry Circ Cardiovasc Interv 7 2014 365 373
24. I. Akin, A.A. Khattab, H.J. Buttner, R. Toelg, V. Geist, F.J. Neumann, G. Richardt, and M. Abdel-Wahab Comparison of bivalirudin and heparin in patients undergoing rotational atherectomy: a subanalysis of the randomised ROTAXUS trial EuroIntervention 10 2014 458 465
25. A. Kastrati, F.J. Neumann, J. Mehilli, R.A. Byrne, R. Iijima, H.J. Buttner, A.A. Khattab, S. Schulz, J.C. Blankenship, J. Pache, J. Minners, M. Seyfarth, I. Graf, K.A. Skelding, J. Dirschinger, G. Richardt, P.B. Berger, A. Schomig ISAR-REACT 3 Trial Investigators Bivalirudin versus unfractionated heparin during percutaneous coronary intervention N Engl J Med 359 2008 688 696
26. G. Parodi, A. Migliorini, R. Valenti, B. Bellandi, U. Signorini, G. Moschi, P. Buonamici, G. Cerisano, and D. Antoniucci Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial) Am J Cardiol 105 2010 1053 1059
27. G. Patti, V. Pasceri, L. D'Antonio, A. D'Ambrosio, M. Macri, G. Dicuonzo, G. Colonna, A. Montinaro, and G. Di Sciascio Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage during Angioplasty-Bivalirudin vs Heparin study) Am J Cardiol 110 2012 478 484
28. P.G. Steg, A. van 't Hof, C.W. Hamm, P. Clemmensen, F. Lapostolle, P. Coste, J. Ten Berg, P. Van Grunsven, G.J. Eggink, L. Nibbe, U. Zeymer, M. Campo dell' Orto, H. Nef, J. Steinmetz, L. Soulat, K. Huber, E.N. Deliargyris, D. Bernstein, D. Schuette, J. Prats, T. Clayton, S. Pocock, M. Hamon, P. Goldstein EUROMAX Investigators Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
29. R. Waksman, O. Bertrand, M. Driesman, L. Gruberg, J. Rossi, S. Mehta, S. Swymelar, D. Dvir, Z. Xue, and R. Torguson Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III) J Interv Cardiol 26 2013 107 113
30. D.C. Xiang, X.L. Gu, Y.M. Song, W.J. Huang, L.Q. Tang, Y.H. Yin, S.H. Geng, H. Zhou, W.M. Fan, R. Hu, C.M. Pan, Y. Zhang, F.Y. Xiao, H.B. Wan, and Z.Z. Liu Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention Chin Med J 126 2013 3064 3068
31. S. Schulz, G. Richardt, K.L. Laugwitz, T. Morath, J. Neudecker, P. Hoppmann, R. Mehran, A.H. Gershlick, R. Tolg, K. Anette Fiedler, M. Abdel-Wahab, S. Kufner, S. Schneider, H. Schunkert, T. Ibrahim, J. Mehilli, A. Kastrati Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction Eur Heart J 35 2014 2285 2294
32. C. Briguori, G. Visconti, A. Focaccio, M. Donahue, B. Golia, L. Selvetella, and B. Ricciarelli Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting through the femoral approach. Rationale and design Cardiovasc Drugs Ther 28 2014 273 279
33. Y. Han, J. Guo, Y. Zheng, H. Zang, X. Su, Y. Wang, S. Chen, T. Jiang, P. Yang, J. Chen, D. Jiang, Q. Jing, Z. Liang, H. Liu, X. Zhao, J. Li, Y. Li, and B. Xu G.W. Stone and BRIGHT Investigators, Bivalirudin versus heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial JAMA 313 2015 1336 1346
34. A. Feldman, K. Suleiman, L. Bushari, M. Yahalom, E. Rozner, N.A. Freedberg, and Y. Turgeman Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding Int J Angiol 23 2014 227 232
35. M. Valgimigli, E. Frigoli, S. Leonardi, M. Rothenbuhler, A. Gagnor, P. Calabro, S. Garducci, P. Rubartelli, C. Briguori, G. Ando, A. Repetto, U. Limbruno, R. Garbo, P. Sganzerla, F. Russo, A. Lupi, B. Cortese, A. Ausiello, S. Ierna, G. Esposito, P. Presbitero, A. Santarelli, G. Sardella, F. Varbella, S. Tresoldi, N. de Cesare, S. Rigattieri, A. Zingarelli, P. Tosi, A. van 't Hof, G. Boccuzzi, E. Omerovic, M. Sabate, D. Heg, P. Juni, and P. Vranckx Bivalirudin or unfractionated heparin in acute coronary syndromes N Engl J Med 373 2015 997 1009
36. H. Jneid, J.L. Anderson, R.S. Wright, C.D. Adams, C.R. Bridges, D.E. Casey Jr., S.M. Ettinger, F.M. Fesmire, T.G. Ganiats, A.M. Lincoff, E.D. Peterson, G.J. Philippides, P. Theroux, N.K. Wenger, and J.P. Zidar 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
37. P.G. Steg, S.K. James, D. Atar, L.P. Badano, C. Blomstrom-Lundqvist, M.A. Borger, C. Di Mario, K. Dickstein, G. Ducrocq, F. Fernandez-Aviles, A.H. Gershlick, P. Giannuzzi, S. Halvorsen, K. Huber, P. Juni, A. Kastrati, J. Knuuti, M.J. Lenzen, K.W. Mahaffey, M. Valgimigli, A. van 't Hof, P. Widimsky, and D. Zahger ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
38. D. Capodanno, G. Gargiulo, P. Capranzano, R. Mehran, C. Tamburino, and G.W. Stone Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials Eur Heart J Acute Cardiovasc Care 2015 pii: 2048872615572599; [Epub ahead of print]
39. S. Cassese, R.A. Byrne, K.L. Laugwitz, H. Schunkert, P.B. Berger, and A. Kastrati Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials EuroIntervention 11 2015 196 203
40. C.S. Kwok, M.A. Khan, S.V. Rao, T. Kinnaird, M. Sperrin, I. Buchan, M.A. de Belder, P.F. Ludman, J. Nolan, Y.K. Loke, and M.A. Mamas Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis Circ Cardiovasc Interv 8 2015 e001645
41. F.W. Verheugt, S.R. Steinhubl, M. Hamon, H. Darius, P.G. Steg, M. Valgimigli, S.P. Marso, S.V. Rao, A.H. Gershlick, A.M. Lincoff, R. Mehran, and G.W. Stone Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention JACC Cardiovasc Interv 4 2011 191 197
42. M. Hamon, P. Coste, A. Van't Hof, J. Ten Berg, P. Clemmensen, X. Tabone, H. Benamer, S.D. Kristensen, C. Cavallini, A. Marzocchi, C. Hamm, V. Kanic, D. Bernstein, P. Anthopoulos, E.N. Deliargyris, and P.G. Steg Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial Circ Cardiovasc Interv 8 2015 e002049
43. M. Valgimigli, A. Gagnor, P. Calabro, E. Frigoli, S. Leonardi, T. Zaro, P. Rubartelli, C. Briguori, G. Ando, A. Repetto, U. Limbruno, B. Cortese, P. Sganzerla, A. Lupi, M. Galli, S. Colangelo, S. Ierna, A. Ausiello, P. Presbitero, G. Sardella, F. Varbella, G. Esposito, A. Santarelli, S. Tresoldi, M. Nazzaro, A. Zingarelli, N. de Cesare, S. Rigattieri, P. Tosi, C. Palmieri, S. Brugaletta, S.V. Rao, D. Heg, M. Rothenbuhler, P. Vranckx, P. Juni MATRIX Investigators Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial Lancet 385 2015 2465 2476